Sep 2026· Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology· Vol 42 9, pp.
827-836
· 0 citations
Medicine
TL;DR
This review summarizes the discovery and structural characteristics of nanobodies, the construction strategies for NDCs, their applications in tumor therapy, and the synergistic potential of nanobodies with other treatment modalities to provide insights for future research and development of NDCs in oncology.
These findings highlight nanobodies as versatile platforms capable of overcoming key limitations of conventional therapies and facilitating clinical translation in precision oncology.
G. Romero-Hernández, Mario S. Valdés-Tresanco, Ernesto Moreno· Cell Biochemistry and Biophy...· 0 citations
The mini-review outlines the development of active targeting approaches, recent progress in the design of intelligent nanomedicine empowered by biomarkers, selected clinical advances, current clinical trials, and future prospects that could expedite the clinical translation of precision nanomedicine to the mainstream c...
M. Karthick, Rajesh Akkena, K. Loganathan· BOHR Journal of Pharmaceutic...· 0 citations
Nanobodies (Nbs), also known as variable domains of camelid heavy-chain-only antibodies (VHHs), have emerged as promising biomolecules in antiviral diagnostics and therapeutics because of their small molecular size, high stability, strong antigen-binding affinity, and ease of genetic engineering. Compared with conventi...
Maryam Mohebbi, S. H. Monavari, Naghmeh Hadidi et al.· Protein Expression and Purif...· 0 citations
Abstract Conventional antibody–drug conjugates (ADCs) are typically limited to drug-to-antibody ratios (DARs) of ≤8 because of restricted conjugation sites and unfavorable physicochemical properties at higher DARs, including increased hydrophobicity, aggregation, and rapid systemic clearance. Consequently, most clinica...
Hao-Sheng Feng, Bin Liu· Antibody Therapeutics· 0 citations
This comprehensive review on Nanotechnology focuses on the entire spectrum of ovarian cancer management and recent advances in physicochemical properties, PK/BD, diagnostic biosensors, treatment modalities to reverse MDR, immunomodulation and personalized nanomedicine are summarized.
Sudhaker Raboni Grace, Mano Magdalin Rubella Kennedy, I. V. Enoch· BioNanoScience· 0 citations
A framework that overcomes the internalization barrier, broadening the target scope for therapeutic and diagnostic conjugates is established and extended BTR to programmed cell death ligand 1 (PD-L1) and an mRNA-display-derived FAP peptide, suggesting potential broad applicability.
Zihao Wen, Mengxin Xu, Zi-Jun Yan et al.· Nature· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
